Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
06 avr. 2022 08h00 HE
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital
04 avr. 2022 16h05 HE
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
21 mars 2022 16h05 HE
|
Viridian Therapeutics, Inc.
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care - - Top line results from...
Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
14 mars 2022 16h05 HE
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
10 mars 2022 16h05 HE
|
Viridian Therapeutics, Inc.
-- Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 -- ...
Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
03 mars 2022 16h16 HE
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
14 févr. 2022 08h00 HE
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
31 janv. 2022 07h00 HE
|
Viridian Therapeutics, Inc.
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection -- Company expects to report top line VRDN-002 Phase 1...
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
04 janv. 2022 07h00 HE
|
Viridian Therapeutics, Inc.
- VRDN-002 is a novel anti-IGF-1R monoclonal antibody for thyroid eye disease and incorporates half-life extension technology designed to improve dosing and administration - - Company...
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
20 déc. 2021 07h00 HE
|
Viridian Therapeutics, Inc.
- VRDN-001 targets and blocks IGF-1R, the only mechanism of action proven to deliver efficacy in TED -- Trial is on track to deliver top line proof of concept clinical data in 2Q 2022 - WALTHAM,...